CD226 and neoplasm: Although this defines a key new concept in understanding checkpoint inhibitors in cancer, we must note that TIGIT may also have additional roles in the anti-tumor response that may be CD226 independent, as evidenced by some single activity of anti-TIGIT mAb in CD226-deficient mice and when anti-TIGIT mAb is used in the preventative setting.